Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Ltd. (PAR) is an Australian biopharmaceutical company focused on the development and commercialization of pentosan polysulfate sodium (PPS) for the treatment of musculoskeletal disorders. The company is primarily engaged in researching and developing PPS as a potential therapeutic for conditions such as osteoarthritis and other inflammatory diseases. Paradigm Biopharmaceuticals operates within the pharmaceutical and biotechnology sectors, leveraging its expertise to address unmet medical needs in chronic pain and inflammation management.